Unión Europea - español - EMA (European Medicines Agency)

pharmaxis europe limited - manitol - fibrosis quística - preparaciones para la tos y el resfriado - bronchitol está indicado para el tratamiento de la fibrosis quística (fq) en adultos mayores de 18 años como terapia complementaria al mejor estándar de atención.

Unión Europea - español - EMA (European Medicines Agency)

teva b.v. - colistimetato de sodio - fibrosis quística - antibacterianos para uso sistémico, - colobreathe está indicado para el tratamiento de infecciones pulmonares crónicas causadas por pseudomonas aeruginosa en pacientes con fibrosis quística (fq) mayores de seis años.. se debe dar consideración a las directrices oficiales sobre el uso adecuado de agentes antibacterianos.

Unión Europea - español - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - fibrosis quística - otros productos del sistema respiratorio - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 y 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 y 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Unión Europea - español - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - nintedanib - fibrosis pulmonar idiopática - agentes antineoplásicos - ofev está indicado en adultos para el tratamiento de la fibrosis pulmonar idiopática (ipf).

Unión Europea - español - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - lumacaftor, ivacaftor - fibrosis quística - otros productos del sistema respiratorio - orkambi comprimidos está indicado para el tratamiento de la fibrosis quística (fq) en pacientes mayores de 6 años y más que son homocigotos para la mutación f508del en el gen cftr. orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Unión Europea - español - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - fibrosis quística - otros productos del sistema respiratorio - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.

Unión Europea - español - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - fibrosis quística - otros productos del sistema respiratorio - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Unión Europea - español - EMA (European Medicines Agency)

axunio pharma gmbh - la pirfenidona - fibrosis pulmonar idiopática - inmunosupresores - pirfenidone aet is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

Unión Europea - español - EMA (European Medicines Agency)

gilead sciences ireland uc - aztreonam lisina - cystic fibrosis; respiratory tract infections - antibacterianos para uso sistémico, - cayston está indicado para la terapia supresiva de las infecciones pulmonares crónicas debidas a pseudomonas aeruginosa en pacientes con fibrosis quística (fq) de 6 años o más. se debe dar consideración a las directrices oficiales sobre el uso adecuado de agentes antibacterianos.

Unión Europea - español - EMA (European Medicines Agency)

roche registration gmbh - la pirfenidona - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - inmunosupresores - esbriet is indicated in adults for the treatment of idiopathic pulmonary fibrosis.